Human A
The invention provides the structure of human A 2A adenosine receptor protein bound to an antagonist. Methods of using one or more binding sites and other features of this G-protein coupled receptor to develop new therapeutics are also disclosed.
1. A crystalline form of a human A 2A adenosine receptor protein in complex with (4-(2-[7-amino-2-(2-furyl)-[1,2,4]triazolo-[2,3-a][1,3,5]triazin-5-ylamino]ethyl)-phenol (ZM241385), wherein the human A 2A adenosine receptor protein comprises the amino acid sequence of SEQ ID NO: 1 and the crystalline form is of space group P2 1 and has unit cell dimensions of a=47.7±0.5 Angstroms, b=76.9±0.5 Angstroms, and c=86.8±0.5 Angstroms, and β=101.3°.
2. The crystalline form of claim 1 , wherein said human A 2A adenosine receptor protein comprises a binding pocket I site, and wherein said binding pocket I comprises a plurality of amino acid residues selected from the group consisting of Phe168 5.29 , Ile274 7.39 , Glu169 5.30 , Leu249 6.51 , and Asn253 6.55 .
3. The crystalline form of claim 1 , wherein said human A 2A adenosine receptor protein comprises a binding pocket II site, and wherein said binding pocket II comprises amino acid residues Phe62 2.60 , Ile66 2.64 , Ile80 3.28 , Val84 3.32 , Phe168 5.29 , Leu249 6.51 , Ile274 7.39 and His278 7.43 .
4. The crystalline form of claim 1 , wherein said human A 2A adenosine receptor protein comprises a binding pocket III site, and wherein said binding pocket III site comprises a plurality of amino acid residues selected from the group consisting of Leu48 2.46 , Ala51 2.49 , Asp52 2.50 , Val55 2.53 , Val84 3.32 , Leu87 3.35 , Thr88 3.36 , Ser91 3.39 , Leu95 3.43 , Ile238 6.40 , Phe242 6.44 , Trp246 6.48 , Ser277 7.42 , His278 7.43 , Asn280 7.45 , Ser281 7.46 and Asn284 7.49 .